← Leaderboards
Bridget Kelly Marcellino
Icahn School Of Medicine At Mount Sinai
$1,323,486
Attributed
$1,323,486
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $445.9K · FY2023–25$500K$375K$250K$125K$0
'23
'24
'25
Funding mix
By agency
NIH$1,323,486 · 2
By mechanism
P01$830,274 · 1
K08$493,212 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Saghi Ghaffari$11,733,780
- John Mascarenhas$6,187,399
- Carol Prives$28,176,184
- Lars Pache$1,948,805
- James J Bieker$21,475,352
Others in their field
Other Rising Stars on “Lead”
- Richard Smith · Medical Device Innovation Consortium$41,401,350
- Julia Louise Moore Vogel · Scripps Research Institute, The$32,252,685
- Jinsy Andrews · Columbia University Health Sciences$21,294,649
- Jonathan H Elias · Association Of Universities For Research In Astronomy, Inc.$16,042,279
- Kevin V Grimes · Stanford University$14,783,804
- Xuping Xie · University Of Texas Med Br Galveston$13,737,799
Research focus
LeadSpecimenResourcesMutationAutomobile DrivingHematopoietic Stem CellsInstitutionMyeloproliferative DiseaseStem CellsAccurate DiagnosisCareer DevelopmentBurden Of IllnessCell LineCell ProliferationApoptosisConsentBlood Cell CountClinical Research SiteClinical PhenotypeBlast PhaseClinical TrialsCollaborationsCommunitiesBiochemical
Grant awards (6)
Core B: MPN-RC Tissue Bank$281,449
P01 · FY2025 · CA · contact PI
The Role of PPM1D in Myeloproliferative Neoplasms$164,404
K08 · FY2025 · HL · contact PI
Core B: MPN-RC Tissue Bank$267,376
P01 · FY2024 · CA · contact PI
The Role of PPM1D in Myeloproliferative Neoplasms$164,404
K08 · FY2024 · HL · contact PI
Core B: MPN-RC Tissue Bank$281,449
P01 · FY2023 · CA · contact PI
The Role of PPM1D in Myeloproliferative Neoplasms$164,404
K08 · FY2023 · HL · contact PI